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ABSTRACT
Objective: Crohn’s disease is a chronic inflammation of the gastrointestinal tract 
with an abnormal immune phenotype. We investigated how intracellular calcium 
kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 
channels in pediatric Crohn’s disease.
Study design: Blood was taken from 12 healthy and 29 Crohn’s disease children. 
Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab 
treatment. Intracellular calcium levels were monitored using flow cytometry in the 
presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels.
Results: In Crohn’s disease treated with standard therapy, calcium response 
during activation was higher than normal in Th2 cells. This was normalized in vitro 
by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, 
potassium channel function and expression in Th2 lymphocytes were comparable to 
those in Th1 cells.
Conclusion: These results may indicate that potassium channels are potential 
immune modulatory targets in Crohn’s disease. 
INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory 
disease of the bowels [1]. Immune dysfunction, 
particularly that of adaptive immunity leading to a pro-
inflammatory status is a characteristic hallmark and an 
important contributing factor in CD [2]. Locally, in the 
inflamed lamina propria the number of pro-inflammatory 
Th1 and Th17 cells is elevated [3, 4], while that of anti-
inflammatory Treg cells is decreased. 
In addition to the altered immune phenotype, short-
term activation characteristics of T cells may be also 
abnormal in CD [5, 6]. This is represented by changes in 
calcium handling during T cell activation. The biphasic 
calcium signal that occurs following the T cell receptor 
stimulation is an essential part of the activation process 
evoked by antigen binding to the T cell receptor. During 
the first part of activation, the intracellular stores extrude 
calcium into the cytosolic compartment, then the depletion 
of the endoplasmic reticulum (ER) evokes the calcium 
influx from the extracellular space via store operated 
calcium channels (SOCE) [7]. To maintain the negative 
membrane potential, and to sustain further calcium entry 
into the cells, potassium ions efflux from the cells through 
the voltage gated Kv1.3 and calcium sensitive IKCa1 
potassium channels [8]. 
Our research group had investigated intracellular 
calcium kinetics during stimulation of different T cell 
subsets with a specific novel flow cytometry method. This 
method is able to describe the kinetic change that occurs 
during the measurement by fitting different functions to 
the kinetic parameter values [9]. Different parameters of 
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these functions are comparable in an objective manner. 
With the use of this method, we performed measurements 
in different age groups [10] and pathological conditions. 
We have demonstrated distinct calcium handling profiles 
of Th1, Th2, Th17 and Treg cells in healthy adults [11]. In 
addition, we also reported that autoimmune disorders have 
a major impact on T cell calcium homeostasis. During the 
short-term activation of peripheral T cells in patients with 
rheumatoid arthritis (RA) [12], multiple sclerosis [13] 
and type 1 diabetes [14], we found altered intracellular 
calcium kinetics, that were, at least partly, attributed 
to altered function and/or expression of lymphocyte 
potassium channels. We also demonstrated that some 
immune modulatory therapies, also used in CD, may have 
an impact on T cell function. Indeed, biological agents 
including infliximab (IFX) normalized calcium response 
during short term stimulation of peripheral T cells in RA 
[15].
In this study we investigated calcium handling of 
Th1 and Th2 cells and the function of major lymphocyte 
potassium channels in pediatric CD patients treated with 
different therapeutic regimes.
Based on earlier results in other autoimmune 
conditions, we hypothesized that lymphocyte calcium 
influx kinetics may be altered in pediatric CD. We also 
hypothesized that different groups created by disease 
severity would show distinct lymphocyte potassium 
channel expression and sensitivity to selective blockers.
RESULTS
Laboratory parameters
Laboratory parameters (Table 1) indicate that 
neutrophil percentages were significantly higher in CD 
patients compared to healthy children, while lymphocyte 
percentages were decreased. C-reactive protein (CRP) 
values were higher in the moderate-severe group before 
IFX therapy, but not significantly different from the 
control and conventional groups. IFX therapy decreased 
Pediatric Crohn’s Disease Activity Index (PCDAI) scores 
as well as the elevated CRP levels.
Immune phenotype
The prevalence of Th1 cells was higher than normal 
in CD (Table 2). In the moderate-severe disease group, 
before the 1st IFX therapy, the percentage of Th2 cells 
increased in peripheral blood. After the 4th IFX therapy, 
the ratio of Th1/Th2 further increased.
Calcium influx characteristics
Our results show that in healthy children Th1 and 
Th2 cells have similar calcium influx characteristics upon 
activation (Table 3A). In CD, Th2 cells show intensified 
calcium influx compared to Th1 subpopulation. Although 
Table 1: Clinical parameters of the investigated children
Healthy children
n = 12
Conventional therapy
n = 23
Before 1st IFX
n = 6
After 4th IFX
n = 6
Age (years) 13[10-16]
15
[9-17]
16
[14-17]
16
[14-17]
Gender (boy/girl) 5/7 9/14 3/3 3/3
C- reactive protein 
(mg/L)
2
[1-3]
6
[0-24]
31
[8.75-41.25]
1.50c
[0.25-5.75]
White Blood Cell 
(G/L)
6.50
[5.53-7.15]
6.70
[5.90-9.20]
9.70
[6.28-12.38]
6.00
[4.80-9.60]
Neutrophill 
Granulocyte (% of 
White Blood Cells)
49.90
[47.50-57.20]
61.40a
[58.60-66.60]
73.60a
[66.40-79.23]
69.30a
[65.18-74.63]
Lymphocyte (% of 
White Blood Cells)
38.50
[34.70-43.70]
21.30a
[18.20-28.90]
18.60a
[13.85-20.88]
20.25a
[16.65-26.10]
Thrombocyte 
Platelet (G/L)
374
[325-396]
401
[294-565]
465
[429-584]
342
[287-378]
Pediatric Crohn’s 
Disease Activity 
Index
- 10[5-35]
36b
[35-39]
0c
[0-7.5]
Data are presented as median [IQR]. a p < 0.05 vs. Healthy children, b p < 0.05 vs. Conventional therapy, c p < 0.05 vs. Before 
1st  IFX
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Start values were similar, the Maximum, and Area Under 
the Curve (AUC) values were significantly higher in Th2 
cells. This elevated calcium signal was normalized in the 
presence of both margatoxin (MGTX) and triarylmethane 
(TRAM-34) potassium channel inhibitors (Figure 1). 
Potassium channel inhibitors only had an effect on the 
calcium homeostasis of Th2 cells, while that of the Th1 
subset remained unaffected. 
In the moderate-severe disease group, before the 1st 
IFX therapy, Th2 predominance was observed compared 
to the results of healthy controls and classically treated 
patients (Figure 1). This predominance can be observed 
not only in Maximum and AUC values, but in the Start 
values as well. Th1 cells of the moderate-severe disease 
group did not show altered calcium influx following 
activation compared to the other groups (Table 3B). The 
elevated calcium influx characteristics of Th2 cells were 
normalized by both MGTX and TRAM-34.
IFX therapy evoked a massive effect on calcium 
homeostasis of Th2 cells, reflected by the normalization 
Table 2: Distribution of Th1 and Th2 cells in the different groups
Healthy Children 
controlls
Conventionally treated 
CD
Moderate-severe CD Before 
1st IFX therapy
Moderate-severe 
CD After 4th IFX 
therapy
Th1%/ 
lymphocytes
10,73
[0,52-30,80]
17,90
[0,32-49,34]
21,84
[2,10-39,27]
33,05
[2,01-43,89]
Th2%/ 
lymphocytes
13,99
[0,91-31,60]
9,09
[0,42-49,35]
13,72
[1,16-23,68]
19,53
[3,22-44,50]
Th1%/Th2% 0,77 1,97 1,59 1,69
Data are presented as median [range].
Table 3A: Calcium influx parameters and Kv1.3 channel expression data of healthy controls and conventionally 
treated CD patients
Healthy Children
No inhibitor Mgtx (4 nM) TRAM-34 (240 nM)
Th1 Th2 Th1 Th2 Th1 Th2
Starting value 
(MFI/102)
226
[136-332]
194
[125-281]
192
[106-299]
181
[108-301]
152
[133-194]
158
[137-197]
Maximum value 
(MFI/102)
234
[139-364]
391
[134-2919]
225
[115-384]
214
[118-397]
196
[171-241]
261
[193-265]
Slope at first 50% 
value
301
[1-10321]
3258
[105-175245]
24
[10-1726]
20
[4-479]
26
[22-37]
39
[14-57]
AUC
(MFI/105)
140
[95-201]
168
[77-563]
128
[66-183]
118
[68-186]
102
[97-130]
126
[106-140]
MFI Anti-Kv1.3 91[15-669]
160
[10-1194]
Conventionally treated CD
No inhibitor Mgtx (4 nM) TRAM-34 (240 nM)
Th1 Th2 Th1 Th2 Th1 Th2
Starting value 
(MFI/102)
293
[120-854]
394
[145-1413]
193
[108-552]
216
[107-689]
232
[15-619]
223
[146-570]
Maximum value 
(MFI/102)
340
[171-1099]
1094
[148-2588]b
229
[115-663]
246
[113-815]a
289
[31-754]
307
[191-782]a
Slope at first 50% 
value
69
[2-10262]
123
[5-19105]
97
[1-3126]
31
[1-5402]
174
[1-2491]
170
[13-30706]
AUC
(MFI/105)
178
[102-411]
338
[132-1054]b
127
[66-374]
135
[65-413]a
170
[9-414]
169
[97-431]a
MFI Anti-Kv1.3 179[52-1191]
358
[67-1315]b
Data are presented as median [IQR], a:p < 0.05 vs. no inhibitor (control) treatment in same disease group, same cell subset; 
b:p < 0.05 vs. Th1 cell values in same disease group, same inhibitor treatment; c:p < 0.05 vs. Healthy children in same cell 
subset, same inhibitor treatment;e:p < 0.05 vs. Conventional therapy in same cell subset, same inhibitor treatment; f:p < 0.05 
vs. Before IFX therapy in same cell subset, same inhibitor treatment
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Figure 1: AUC parameter changes of the cytoplasmic calcium concentration altered by potassium channel inhibitors 
following PHA activation of A: Th1 and B: Th2 cells (median, IQR). *p < 0.05.
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of Start, Maximum, AUC, and even Slope values. MGTX 
and TRAM-34 did not evoke further decrease on calcium 
levels in the IFX treated group.
Kv1.3 potassium channel expression
In healthy children, the voltage gated Kv1.3 
potassium channel expression was comparable in Th1 
and Th2 subsets. In CD patients, Th2 cells express Kv1.3 
potassium channel at a higher rate. In moderate-severe 
patients before the 1st IFX therapy, Th2 cells showed 
higher median value of expression than Th1 cells. After 
the 4th IFX therapy, this difference decreased to nearly 
equal levels.
DISCUSSION
In this study we investigated routine laboratory 
parameters, distribution and calcium influx characteristics 
of Th1 and Th2 cell subpopulations, and their Kv1.3 
potassium channel expression in classically and IFX 
treated pediatric CD patients.
Routine laboratory parameters indicated higher 
neutrophil and lower lymphocyte percentages in the CD 
groups. CRP values were also elevated in the moderate-
severe group before IFX treatment and were restored 
to normal levels by IFX. These findings are in line with 
earlier results [16]. PCDAI scores were above 30 in the 
moderate-severe group before IFX therapy. The efficacy of 
IFX therapy is indicated by a notable decrease in PCDAI 
scores.
Interestingly, phenotypic alterations indicated higher 
percentages of Th1 within the lymphocyte population in 
classically treated CD. This elevated prevalence of Th1 
cells in the peripheral blood further increased in the 
moderate-severe group before the 1st IFX therapy. IFX 
treatment did not decrease the percentages of Th1 cells 
in the peripheral blood, but the prevalence of Th2 cells 
was increased [4]. However, since lymphocyte counts are 
higher in healthy controls, the absolute number of Th1 
cells is only higher in the moderate to severe CD group. 
Likewise, the absolute number of Th2 cells is lower in 
CD patients than normal and decreased after infliximab 
treatment due to the lower lymphocyte counts in these 
patients following infliximab therapy. The migration 
of Th1 cells into the inflamed lamina proparia from the 
periphery might also play a role in this phenomenon. This 
Table 3B: Calcium influx parameters and Kv1.3 channel expression data of  the moderate-severe CD group
Before 1st IFX therapy
No inhibitor Mgtx  (4 nM) TRAM-34 (240 nM)
Th1 Th2 Th1 Th2 Th1 Th2
Starting value 
(MFI/102)
400
[330-566]
1023
[100-2597] b,c,e
329
[257-493]
340
[272-614]a
399
[2-669]
432
[1-617] a
Maximum value 
(MFI/102)
436
[393-583]
2233
[1176-2621] b,c,e
393
[361-550]
387
[364-798]a
407
[2-805]
455
[10-794] a
Slope at first 50% 
value
2665
[81-21390]
8531
[156-129330] e
90
[30-4543]
59
[25-10837]a
710
[23-4167]
3187
[1-7725] a
AUC
(MFI/105)
236
[199-283]
709
[279-1572] b,c,e
203
[157-296]
213
[169-328] a
241
[1-513]
263
[5-375] a
MFI Anti-Kv1.3 165[87-1230]
327
[86-413]
After 4th IFX therapy
No inhibitor Mgtx (4 nM) TRAM-34 (240 nM)
Th1 Th2 Th1 Th2 Th1 Th2
Starting value 
(MFI/102)
260
[127-495]
546
[216-1136]f
237
[162-402]
247
[162-390]
254
[74-496]
266
[77-712]
Maximum value 
(MFI/102)
276
[154-315]
904
[306-1813]f 
213
[88-320]
244
[88-551]
260
[91-512]
292
[90-231]
Slope at first 50% 
value
81
[2-10178]
195
[21-1146]f
30
[8-63]
31
[6-81]
1276
[32-3517]
908
[21-17080]
AUC
(MFI/105)
155
[83-187]
293
[170-894]b,f
153
[105-280]
146
[50-298]
155
[51-298]b
159
[51-242]
MFI Anti-Kv1.3 122[49-983]
99
[48-178]
Data are presented as median [IQR], a:p < 0.05 vs. no inhibitor (control) treatment in same disease group, same cell subset; 
b:p < 0.05 vs. Th1 cell values in same disease group, same inhibitor treatment; c:p < 0.05 vs. Healthy children in same cell 
subset, same inhibitor treatment;e:p < 0.05 vs. Conventional therapy in same cell subset, same inhibitor treatment; f:p < 0.05 
vs. Before IFX therapy in same cell subset, same inhibitor treatment.
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presumption needs to be verified by further investigations 
in the future.
Our results on calcium influx kinetics clearly 
indicated a distinct profile of classically treated CD 
from age-matched healthy individuals. This is similar to 
previous findings of our team in autoimmune disorders 
like rheumatoid arthritis and type 1 diabetes [12, 14], 
which were also characterized by a significant alteration 
of T cell calcium influx kinetics.
Th2 cells in the conventionally treated group and 
in moderate-severe patients before IFX treatment showed 
higher initial and peak cytoplasmic calcium concentrations 
as well as AUC values, hence this may indicate that this 
subpopulation is more active during early phase signaling 
compared to Th1 cells. At the first glance, this is in 
contrast with findings describing that CD is a Th1 type 
disorder [17, 18]. The difference may come from the fact 
that most of the studies were performed on adult patients 
and describe the local cytokine and cellular milieu in the 
gut. Instead, studies that investigated pediatric subjects 
also found a shift toward Th2 populations in the peripheral 
blood [19]. This shift observed in the bloodstream might 
partially be due to the extravasation of Th1 cells in the gut, 
however, it is not confirmed by prevalence values of the 
current study. While the conclusion of others was based on 
prevalence data of the distinct T cell subsets, our results 
give further information about the function of these cells. 
One of our most interesting observation comes from 
the measurements performed on the group where blood 
samples were obtained before the first and after the 4th 
IFX therapy on patients with an initial PCDAI score > 30. 
Paired sample analysis of this group indicated that IFX 
has a clear effect on calcium influx characteristics of Th2 
cells. This effect has never been mentioned before in the 
literature, and it is unclear which signaling pathway is 
responsible for the observed phenomenon. We hypothesize 
that the chimeric antibody may alter the surface expression 
of calcium (e.g. SOCE, Cav1) or potassium channels 
(IKCa1, Kv1.3) on lymphocytes, as it is a high molecular 
weight protein, hence it cannot penetrate the cell 
membrane and alter other intracellular channels that are 
crucial to calcium homeostasis of the cells, such as the 
sarco/endoplasmic reticulum calcium ATPase (SERCA), 
or ryanodine receptors [20]. The identification of the exact 
signaling pathways requires further specific studies aimed 
at detecting the affected messenger molecules.
Figure 2: Investigated parameters of the double logistic function of cytoplasmic calcium concentration.
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The investigated potassium channels have a 
crucial role in the altered early phase T cell activation 
in pediatric CD. Application of selective blockers of 
the IKCa1 and Kv1.3 potassium channels is a possible 
new target for autoimmune therapy [21], and in a colitis 
murine model they already proved to be effective and 
fairly selective for the over-activated cell types [22]. In 
our study we could justify that both MGTX and TRAM 
has the potential to lower the increased calcium influx 
in Th2 cells nearly to the level observed in healthy 
individuals in case of the conventionally treated group. 
This effect may be due to the higher expression of Kv1.3 
potassium channels on Th2 cells. This result is in line 
with other studies showing that the expression of Kv1.3 
was elevated on the surface of CD4+ cells in ulcerative 
colitis, and levels of Kv1.3 correlate well with the higher 
expression of TNF-α, and may serve as a good marker 
of disease activity [21]. Hansen et al. also found Kv1.3 
and IKCa1 potassium channels to be to be important in 
ulcerative colitis and declared them as possibly relevant 
pharmacological targets [5]. Furthermore, our results on 
potassium channel inhibition are similarly promising as 
the findings of Di Sabatino et al., who found the calcium 
release activated (CRAC) channel inhibition on lamina 
propria mononuclear cells (LPMC) may have beneficial 
therapeutic effects [23].
We also investigated the effect of lymphocyte 
potassium channel inhibition on the samples of moderate-
severe, IFX treated subjects. We found that the decrease 
in intracellular calcium concentration induced by IFX 
cannot be further enhanced by the application of MGTX 
or TRAM. This seems to be logical, since the calcium 
homeostasis of T cells is regulated precisely [20], and a 
basal level of calcium is necessary for the proper function 
of resting lymphocytes, thus controlling biochemical 
mechanisms do not allow an extreme degree of alteration. 
Based on our results, the future potential of lymphocyte 
potassium channel inhibitors might be as simultaneous 
therapeutic agents besides IFX therapy, to lower the 
therapeutic dose of IFX. This approach might the 
possibility of decreasing both the cost and side-effects of 
IFX treatment. 
Interestingly, our current results proved to be fairly 
selective in modulation of the abnormal calcium influx 
of peripheral Th2 cells, while our pervious studies show 
only moderate selectivity on CD8 lymphocytes in multiple 
sclerosis or on Th1 cells in type 1 diabetes mellitus [13, 
14].
A limitation of our study is the fact that 
measurements were executed on peripheral blood samples, 
which may not reflect the circumstances in the inflamed 
mucosa. Further studies are needed to investigate whether 
our findings correspond to alterations in tissue samples. 
Another limitation is the small number patients who 
received IFX treatment. Specific signal pathway analysis 
and larger clinical trials will help support our conclusions.
Keeping in mind the above limitations, we 
conclude that the observed functional Th2 predominance 
in peripheral blood of pediatric CD patients might be 
shifted to normal values by inhibitors of Kv1.3 and IKCa1 
lymphocyte potassium channels. IFX therapy may also 
reduce the elevated activation of the Th2 subset in patients 
with severe symptoms. The potential simultaneous 
application of these agents with IFX require further 
studies, as they appear to be promising novel therapeutic 
alternatives or complements of IFX therapy. Further 
investigations performed on gut biopsy samples are also 
needed to confirm the relevance of our findings. 
MATERIALS AND METHODS
Sample collection
Peripheral blood samples were taken from 12 
healthy children (5 boys and 7 girls; age: 13 (10-16) 
years, median (interquartile range)), and 23 conventionally 
treated CD patients diagnosed according to the Porto 
criteria system [24], and classified by the PCDAI scale 
[25] (9 boys and 14 girls; age: 15 years (9-17), median 
(interquartile range)). These patients received azathioprine 
and 5-acetylsalicylic acid (5-ASA) or mesalazine without 
systemic steroids. 6 patients (3 boys and 3 girls; age: 
16 years (14-17), median (interquartile range)) with 
a PCDAI score > 30 who were switched to IFX (5mg/
kg) were selected for measurements before the first, 
and after the 4th IFX-treatment. The distribution of the 
diseased intestines was homogenous in all patients with 
no specific predominant localization of the disease. The 
following laboratory parameters were also determined 
using routine laboratory procedures: CRP, White Blood 
Cell (WBC), neutrophil, lymphocyte and thrombocyte 
percentages. Informed consent was obtained from parents 
of all subjects, and our study was reviewed and approved 
by an independent ethical committee of the institution. The 
study was adhered to the tenets of the most recent revision 
of the Declaration of Helsinki.
Calcium influx measurements
Peripheral blood mononuclear cells (PBMCs) were 
separated by a standard density gradient centrifugation 
(25 min, 400 g, 22 oC) from freshly drawn blood. This 
cell suspension was washed twice in PBS. From then 
on, cells were kept throughout staining with fluorescent 
markers, treatment with inhibitors and measurement on 
flow cytometer in a modified RPMI-1640 medium. The 
calcium concentration of this medium was set to 2 mM by 
addition of crystalline CaCl
2
.
PBMCs were incubated with the following anti-
human mAbs: anti-CD4 PE-Cy7 (clone SK3, BioLegend, 
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San Diego, CA, USA), anti-CXCR3 APC (clone 1C6/
CXCR3, BD Biosciences, San Jose, CA, USA), anti-
CCR4 PE (clone 1G1, BD Biosciences) as well as anti-
Kv1.3 FITC (Sigma-Aldrich, St. Louis, MO, USA) 
according to the manufacturers’ instructions. Cytoplasmic 
free calcium levels were detected by loading the cells with 
the 1:2 ratio of Fluo-3-AM and Fura Red fluorescent dyes 
(Biotium, Hayward, CA, USA) and 0.02 % Pluronic F-127 
(Molecular Probes, Carlsbad, CA, USA) for 20 minutes at 
30 oC. Cells were washed once before measurement.
PBMCs were divided into four vials with equal 
cell numbers. One vial was treated with MGTX (4 nM; 
Sigma-Aldrich), a selective blocker of the Kv1.3 channel, 
for 15 min before measurement. Another vial was treated 
with a triarylmethane compound, TRAM-34 (240 nM; 
Sigma-Aldrich), a specific inhibitor of the IKCa1 channel, 
for 10 min before measurement. The third vial was used 
as control. The fourth vial was incubated with 1 µg anti-
Kv1.3 (Sigma-Aldrich) besides the mAbs used for surface 
staining. In all cases, samples were kept at 30o C in dry 
bath, until the measurements.
At the beginning of the kinetic measurements, 
a 2 min baseline of calcium level was recorded. T cell 
activation was initiated by phytohemagglutinin (PHA, 
15 μg/ml final concentration) as described earlier. 
Fluorescence emission of sequentially measured cells 
was monitored for 10 minutes. Average cell acquisition 
rate was 1000 cells/s. In case of the Kv1.3 expression 
measurements, 500.000 cells were recorded, and the mean 
fluorescence intensity (MFI) values were calculated. 
All measurements were performed on a BD 
FACSAria flow cytometer (BD Biosciences). Single-
stained controls were applied to perform compensation.
Data analysis
The population of lymphocytes was gated according 
to forward and side scatter characteristics. CD4+ CXCR3+ 
cells were regarded as Th1 cells, CD4+ CCR4+ cells were 
regarded as Th2 cells population.
Data acquired from the measurements were 
evaluated with specific software developed at our 
laboratory (FacsKin, available at: www.facskin.com). The 
core of this software is an algorithm [26], based on the 
calculation of double-logistic functions for each recording. 
The software also calculates parameter values describing 
each function, such as the start value, representing the 
initial cytoplasmic calcium concentration of resting cells, 
the maximum value, the slope parameter, describing the 
magnitude of increase during calcium influx, and the AUC 
value, corresponding to the sum cytoplasmic calcium 
increase (Figure 2).
Comparisons of the calculated parameters between 
T cell subpopulations in the same patient group as well 
as between patient groups within the same T cell subset 
were made with the Kruskall-Wallis test, while the effect 
of the applied channel blockers were calculated using 
the Wilcoxon-test, as Kolmogorov-Smirnoff analysis 
indicated non-normal distribution of data. Statistics were 
calculated at 5% significance level (p = 0.05) using the 
GraphPad Prism 5 software (La Jolla, CA, USA).
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